Participating Companies

Alladapt Immunotherapeutics, Inc.
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is cur­rent­ly in a Ph 1/2 clin­i­cal trial, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves as Al­la­dapt’s CEO. To date, the com­pany has raised $63 mil­lion. [more in­for­ma­tion]
Amphista Therapeutics
Iden­ti­fied nov­el de­grad­ing mech­anisms in­de­pen­dent of typ­i­cal E3 li­g­as­es • Build­ing on strengths of TPD while di­rect­ly ad­dress­ing lim­i­ta­tions • De­mon­s­trat­ed su­pe­ri­or­i­ty over other TPD ap­proach­es across three se­parate ar­eas: in­creased scope, im­proved drug­like prop­er­ties and re­duced re­sis­tance po­ten­tial • Ini­tial fo­cus in On­col­o­gy with scope to ex­pand in­to fur­ther ther­a­py ar­eas, in­clud­ing CNS dis­eas­es Am­phis­ta Ther­a­peu­tics suc­cess­ful­ly closed an over­sub­scribed $53M Se­ries B round in March 2021, build­ing on an ini­tial $7.5M Se­ries A fund­ing raised in April 2020. [more in­for­ma­tion]
Arbor Biotechnologies
An ear­ly-stage life sci­ences com­pany pi­oneer­ing the next-gen­er­a­tion of ge­net­ic medicines. With the most ex­ten­sive li­brary of CRIS­PR nu­cleas­es in the in­dus­try, a deep bench of world-class foun­ders (in­clud­ing gene edit­ing pi­oneer Feng Zhang) and sci­en­tif­ic ad­vi­sors, and a lead­er­ship team with a proven track re­cord of de­vel­op­ing nov­el plat­forms and ther­a­peu­tics, Ar­bor is well-po­si­tioned to de­vel­op cu­ra­tive ge­net­ic medicines for all pa­tients with ge­net­ic dis­eas­es. [more in­for­ma­tion]
Atomwise
Our Atom­Net® tech­nol­o­gy has been used to un­lock more un­drug­gable tar­gets than any other AI drug dis­cov­ery plat­form. We are tack­ling over 600 unique dis­ease tar­gets with more than 250 part­n­ers around the world, in­clud­ing lead­ing phar­ma­ceu­ti­cal, agro­chem­i­cal, and emerg­ing biotech­nol­o­gy com­pa­nies. [more in­for­ma­tion]
CAMP4
De­vel­op­er of a plat­form to dis­cov­er ef­fec­tive treat­ment ap­proach­es for ev­ery dis­ease. The com­pany's gene cir­cuit­ry plat­form solves the cir­cuit­ry code, unique to each hu­man gene, fa­cil­i­tat­ing the rapid dis­cov­ery of new treat­ments. Its 4D maps iden­ti­fy de-risked drug­gable tar­gets, pro­duce ac­tion­able in­sights and im­prove ther­a­peu­tic pre­dicta­bil­i­ty. [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Catamaran Bio
The Com­pany is us­ing its TAIL­WINDTM Plat­form, an in­te­grat­ed suite of tech­nolo­gies, to spe­cif­i­cal­ly ad­dress the end-to-end meth­ods of en­gi­neer­ing, pro­cess­ing and man­u­fac­tur­ing NK cells and rapid­ly ad­vance its pipe­line of CAR-NK cell ther­a­py pro­grams. [more in­for­ma­tion]
Celsius Therapeutics
Provider of a plat­form in­tend­ed to re­search on sin­gle-cell RNA se­quenc­ing and ge­nom­ic anal­y­sis to de­vel­op life-chang­ing medicines. The com­pany's plat­form ap­plies sys­te­m­at­ic ap­proach to sin­gle-cell se­quenc­ing, com­bin­ing mas­sive da­tasets and al­go­rithms in or­der to dis­cov­er pre­ci­sion ther­a­pies, en­abling doc­tors to im­pact on the lives of pa­tients with au­toim­mune dis­eas­es and can­cer. [more in­for­ma­tion]
Chameleon Biosciences
The com­pany's tech­nolo­gies in­clude ef­fec­tor vec­tors and exo-AAV which are not con­s­trained by the same im­mune sys­tem lim­i­ta­tions that pre­vent more wide­spread use of cur­rent AAV gene ther­a­pies, en­abling pa­tients to treat rare dis­eas­es with ge­net­ic medicines ad­min­is­tered as many times as need­ed. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Om­ni­fo­cal con­tact lens pres­by­opia 510k sub­mis­sion and my­opia pro­gres­sion clin­i­cal da­ta in 2H2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Cytoimmune Therapeutics
We are a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of nov­el can­cer im­munother­a­py prod­ucts de­signed to uti­l­ize the pow­er of the pa­tient’s own im­mune sys­tem to elim­i­nate can­cer cells. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
Enterome
En­terome is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing nov­el drugs based on its unique abil­i­ty to de-code molec­u­lar in­ter­ac­tions in the gut mi­cro­biome im­pact­ing hu­man health. En­terome’s suc­cess is based on its unique abil­i­ty to iden­ti­fy small pro­teins and pep­tides from gut bac­te­ria that can de­liv­er a ther­a­peu­tic ben­e­fit in hu­mans. [more in­for­ma­tion]
Evox Therapeutics
Ex­o­some-based drugs have the po­ten­tial to ad­dress some of the lim­i­ta­tions of pro­tein, anti­body and nu­cle­ic acid-based ther­a­pies by en­abling de­liv­ery to cells and tis­sues that are cur­rent­ly out of reach us­ing other drug de­liv­ery tech­nolo­gies, and Evox is lead­ing the de­vel­op­ment within this emerg­ing ther­a­peu­tic space. [more in­for­ma­tion]
Hangzhou Chance Pharmaceuticals
Chance fo­cus­es on in­ha­la­tion prod­ucts with pro­pri­e­tary tech­nolo­gies. [more in­for­ma­tion]
HotSpot Therapeutics
The com­pany helps to iden­ti­fy hotspots and lo­cate path­way treat­ments for can­cer, metabolic and rare dis­eas­es. Its plat­form lev­er­ages a database of hotspot struc­tures, har­ness­ing the pow­er of da­ta sci­ence in its mul­tidis­ci­pli­nary ap­proach to drug dis­cov­ery. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT and Jun­shi Bio­s­ciences estab­lished a 50:50 joint ven­ture that fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of Se­na­parib in Chi­na. The JV is cur­rent­ly con­duct­ing a Phase II piv­o­tal study and a Phase III study of Se­na­parib in ovarian can­cer third-line treat­ment and first-line main­te­nance treat­ment in Chi­na. [more in­for­ma­tion]
Imvax
Im­vax™ is a clin­i­cal-stage biotech­nol­o­gy com­pany de­vel­op­ing per­so­n­al­ized, whole tu­mor-de­rived im­munother­a­pies. Im­vax’s port­fo­lio in­cludes sev­er­al pro­grams de­signed to sti­m­u­late a pa­tient’s im­mune sys­tem against the en­tire anti­gen sig­na­ture of their tu­mor. Im­vax’s most ad­vanced pro­gram is IGV-001 for the treat­ment of glioblas­to­ma. [more in­for­ma­tion]
Invetx
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Lassen Therapeutics
IL-11, a mem­ber of the IL-6 fam­i­ly of cy­tokines, is a cen­tral me­di­a­tor of fi­bro­sis and block­ing its ac­tiv­i­ty has the po­ten­tial to be more ef­fec­tive than tar­get­ing other fac­tors such as TGF-&be­ta; and CT­GF. IL-11 is al­so a piv­o­tal ef­fec­tor of tu­mor mi­croen­vi­ron­ment or­gani­za­tion and tu­mor growth, play­ing a key role as a me­di­a­tor be­tween can­cer and stro­mal cells. [more in­for­ma­tion]
LiPac Oncology
LI­PAC On­col­o­gy is a phar­ma­ceu­ti­cal com­pany fo­cused on ad­vanc­ing the de­vel­op­ment of new in­vesti­ga­tio­n­al ther­a­pies to treat in­tra­cav­i­tary can­cers. Li­Pax, its lead in­vesti­ga­tio­n­al can­di­date for the treat­ment of non-mus­cle in­va­sive blad­der can­cer, is in Phase 2b de­vel­op­ment. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in a new class of RNA medicines - RNA ac­ti­va­tion (RNAa) ther­a­peu­tics plat­form, ini­tial­ly fo­cus­ing on im­muno-on­col­o­gy and rare dis­ease in­di­ca­tions with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (clin­i­cal POC in 2L HCC), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minerva Biotechnologies
A clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing can­cer im­munother­a­pies and drugs to tar­get 75% of solid tu­mors and to pre­vent can­cer me­tas­ta­sis. Min­er­va has a pipe­line that in­cludes next-gen CAR Ts and other mo­dal­i­ties. The Com­pany has an on­go­ing Phase I/II study of huM­NC2-CAR44, an au­tol­o­gous CAR T ther­a­py, tar­get­ing the tu­mor-as­so­ci­at­ed form of MUC1 (MUC1*) which is a growth fac­tor re­cep­tor that drives growth of an es­ti­mat­ed 93% of breast can­cers. [more in­for­ma­tion]
MISSION Therapeutics
Mis­sion Ther­a­peu­tics is an ear­ly-stage drug de­vel­op­ment com­pany tar­get­ing the ubiquitin path­way for the treat­ment of neu­rode­gen­er­a­tive dis­ease, rare mi­to­chon­drial dis­eas­es and fi­bro­sis. [more in­for­ma­tion]
NKGen Biotech
is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of unique au­tol­o­gous, al­lo­gene­ic, and CAR-NK Na­t­u­ral Killer (NK) Cell ther­a­pies. [more in­for­ma­tion]
NodThera Limited
Op­er­a­tor of a clin­i­cal-stage biotech­nol­o­gy com­pany in­tend­ed to de­vel­op medicines to treat dis­eas­es driv­en by chron­ic in­flam­ma­tion. The com­pany is fo­cused on de­vel­op­ing a new class of po­tent and se­lec­tive NL­R­P3 in­flam­ma­some in­hibi­tors, pro­vid­ing med­i­cal prac­ti­tion­ers with tools to help pa­tients with many chron­ic dis­eas­es. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Lead prod­uct, icos­abu­tate has been found safe and ef­fec­tive in two pri­or phase 2 clin­i­cal studies for treat­ment of hy­per­trig­lyc­eridemia and mixed dys­lipi­demia and is cur­rent­ly in clin­i­cal de­vel­op­ment for NASH. The icos­abu­tate phase 2b ICO­NA NASH trial is sche­d­uled to read­out in the first quar­ter of 2023. Two ad­di­tio­n­al SE­FAs are in clin­i­cal de­vel­op­ment; SE­FA 1024 is in phase 1 to be de­vel­oped for dys­lipi­demia and SE­FA 6179, [more in­for­ma­tion]
OncoResponse
In a broad strate­g­ic al­liance with MD An­der­son Can­cer Cen­ter, On­coRe­sponse de­ploys a pro­pri­e­tary B-cell dis­cov­ery plat­form to iden­ti­fy and de­vel­op nov­el ther­a­peu­tics tar­get­ing the tu­mor mi­croen­vi­ron­ment. [more in­for­ma­tion]
Orum
Strong R&D team with in­dus­try vet­er­ans in mAb/ADC dis­cov­ery and physics based mod­el­ing pro­vides Orum with an un­matched R&D en­gine to dis­cov­er and de­vel­op mul­ti­ple plat­forms with pipe­line prod­ucts with pre­ci­sion and speed. [more in­for­ma­tion]
Plexium
Plex­i­um’s tar­get­ed pro­tein degra­da­tion plat­form, DELPhe®, en­ables the dis­cov­ery of nov­el small molecules with cell-based ac­tiv­i­ty that redi­rect E3 li­g­as­es to patho­genic pro­teins of in­ter­est or in­duce degra­da­tion of patho­genic pro­teins by di­rect­ly bind­ing to them. [more in­for­ma­tion]
Prilenia
Prile­nia is a clin­i­cal stage biotech com­pany, led by Michael Hay­den, MD, PhD., to­gether with a high­ly ex­pe­ri­enced team with a track re­cord of suc­cess. Michael is a world-renowned sci­en­tist in Hunt­ing­ton Dis­ease re­search. He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. The com­pany has re­cent­ly raised $68.5M in a Se­ries A fi­nanc­ing round to launch [more in­for­ma­tion]
PROSION
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Revitope Oncology
The lead­ing next gen­er­a­tion con­di­tio­n­al­ly ac­ti­vat­ed T cell en­gager com­pany lev­er­ag­ing its Two­GATE™ plat­form to ad­dress ar­eas of un­met need for safer and more ef­fec­tive can­cer im­munother­a­pies. Re­vi­tope’sT­wo­GATE™ drugs tar­get a pair of anti­gens co-ex­pressed on the sur­face of can­cer cells to achieve an un­par­al­leled de­gree of tu­mor se­lec­tiv­i­ty and avoid toxic­i­ty on healthy cells and tis­sues.” [more in­for­ma­tion]
Shoreline Biosciences
Shore­line Bio­s­ciences is de­vel­op­ing clin­i­cal­ly ef­fec­tive al­lo­gene­ic, off-the-shelf, tar­get­ed, and stan­dardized im­munother­a­pies us­ing in­tel­li­gent­ly en­gi­neered in­duced Pluripo­tent Stem Cell (iP­SC)-de­rived NK cells and macrophages for se­ri­ous dis­eas­es. [more in­for­ma­tion]
ShouTi Inc.
Shou­Ti’s vi­sion is to im­prove world health by bet­ter treat­ing chron­ic dis­eas­es such as car­dio­vas­cu­lar dis­ease and di­a­betes which are rapid­ly in­creas­ing and rep­re­sent over 60% of the glob­al dis­ease bur­den. Shou­Ti’s first drug can­di­date en­tered hu­man clin­i­cal trials in May 2021 and a se­cond molecule is ex­pect­ed to en­ter the clin­ic in ear­ly 2022. [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
SparingVision
The Com­pany is sup­port­ed by a strong, in­ter­na­tio­n­al­ly renowned team who aim to har­ness the po­ten­tial of ge­nom­ic medicine to de­liv­er new treat­ments to all oc­u­lar dis­ease pa­tients as quick­ly as pos­si­ble. [more in­for­ma­tion]
SphingoTec GmbH
Sphin­goTec’s first-in-class tests are made avai­l­able on its pro­pri­e­tary whole-blood point-of-care Nexus IB10 plat­form for con­ve­nient and rapid test­ing in near-pa­tient and lab­o­ra­to­ry sett­ings along­side a broad port­fo­lio of stan­dard-of-care test for acute care. [more in­for­ma­tion]
Systems Oncology
Dde­vel­op­ing a new class of mul­ti­mo­dal RNA ther­a­peu­tics that si­mul­ta­ne­ous­ly si­lence the right com­bi­na­tion of dis­ease tar­gets with a sin­gle RNA molecule to im­prove out­comes and com­bat emerg­ing drug re­sis­tance. Our Ar­romerTM plat­form is used to dig­i­tal­ly en­gi­neer and rapid­ly pro­duce self-de­liv­er­ing ther­a­peu­tics which are di­rect­ed to spe­cif­ic tis­sues with un­prece­dent­ed pre­ci­sion and ac­cu­ra­cy. We are fo­cused on build­ing a pipe­line of drug prod­ucts in on­col­o­gy, yet our mul­ti­mo­dal RNA ther­a­peu­tics plat­form can be [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. [more in­for­ma­tion]
Totus Medicines
[more in­for­ma­tion]
Treos Bio Limited
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
XyloCor Therapeutics
Xy­lo­Cor Ther­a­peu­tics is a bio-phar­ma­ceu­ti­cal com­pany in­tend­ed to de­vel­op gene ther­a­py for peo­ple with ad­vanced coro­nary artery dis­ease. [more in­for­ma­tion]